ASKA Pharmaceutical Holdings CO., Ltd.
4886.TJapan
18 filed reports · 262 financial concepts
Latest figures
Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.
Latest fiscal year
Latest half year
Filed reports
18 reports · Jun 2021 to Sep 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Annual · annual securities reportEDINET | 5 | 1,471 | Mar 2022 to Mar 2026 |
| Half Year · half-year securities reportEDINET | 3 | 701 | Sep 2024 to Sep 2026 |
| Q3 · quarterly securities reportEDINET | 3 | 350 | Dec 2021 to Dec 2023 |
| Half Year · quarterly securities reportEDINET | 2 | 384 | Sep 2022 to Sep 2023 |
| Q1 · quarterly securities reportEDINET | 2 | 338 | Jun 2022 to Jun 2023 |
| Half Year · amended quarterly securities reportEDINET | 1 | 46 | Sep 2021 |
| Q1 · amended quarterly securities reportEDINET | 1 | 47 | Jun 2021 |
| Q3 · amended quarterly securities reportEDINET | 1 | 42 | Dec 2021 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2027 H1 | half-year securities report | 2026-09-30 | 2026-11-09 | 316 | Open |
| FY2026 | annual securities report | 2026-03-31 | 2026-06-19 | 622 | Open |
| FY2026 H1 | half-year securities report | 2025-09-30 | 2025-11-07 | 194 | Open |
| FY2025 | annual securities report | 2025-03-31 | 2025-06-20 | 281 | Open |
| FY2025 H1 | half-year securities report | 2024-09-30 | 2024-11-08 | 191 | Open |
| FY2024 | annual securities report | 2024-03-31 | 2024-06-25 | 280 | Open |
| FY2024 Q3 | quarterly securities report | 2023-12-31 | 2024-02-09 | 201 | Open |
| FY2024 H1 | quarterly securities report | 2023-09-30 | 2023-11-10 | 192 | Open |
| FY2024 Q1 | quarterly securities report | 2023-06-30 | 2023-08-07 | 195 | Open |
| FY2023 | annual securities report | 2023-03-31 | 2023-06-27 | 257 | Open |
| FY2023 Q3 | quarterly securities report | 2022-12-31 | 2023-02-09 | 147 | Open |
| FY2023 H1 | quarterly securities report | 2022-09-30 | 2022-11-10 | 192 | Open |
Financial data
262 concepts · 3,379 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
GAAP250 concepts · 2,976 facts · Mar 2021 to Sep 2026
- EPS (Basic)37 · Jun 2021 to Sep 2026
- Net Assets32 · Mar 2021 to Sep 2026
- Cash and deposits31 · Jun 2021 to Sep 2026
- Equity-to-asset ratio, Key financial data31 · Jun 2021 to Sep 2026
- Investments and other assets31 · Jun 2021 to Sep 2026
- Net assets, Key financial data31 · Jun 2021 to Sep 2026
- Ordinary profit (loss), Key financial data31 · Jun 2021 to Sep 2026
- Other-CA31 · Jun 2021 to Sep 2026
- Other-CL31 · Jun 2021 to Sep 2026
- Retained Earnings (Accumulated Deficit)31 · Jun 2021 to Sep 2026
- Revenue31 · Jun 2021 to Sep 2026
- Share capital31 · Jun 2021 to Sep 2026
- Shareholders' equity31 · Jun 2021 to Sep 2026
- Short-term borrowings31 · Jun 2021 to Sep 2026
- Total Assets31 · Jun 2021 to Sep 2026
- Total assets, Key financial data31 · Jun 2021 to Sep 2026
- Total Current Assets31 · Jun 2021 to Sep 2026
- Total Current Liabilities31 · Jun 2021 to Sep 2026
- Total Equity and Liabilities31 · Jun 2021 to Sep 2026
- Total Liabilities31 · Jun 2021 to Sep 2026
- Total Noncurrent Assets31 · Jun 2021 to Sep 2026
- Treasury shares31 · Jun 2021 to Sep 2026
- Intangible assets29 · Jun 2021 to Sep 2026
- Investment securities29 · Jun 2021 to Sep 2026
Segment12 concepts · 403 facts · Jun 2021 to Sep 2026
- Operating Income88 · Jun 2021 to Sep 2026
- Revenue88 · Jun 2021 to Sep 2026
- Revenues from external customers71 · Jun 2021 to Sep 2026
- Transactions with other segments51 · Jun 2021 to Sep 2026
- Number of employees27 · Mar 2022 to Mar 2026
- Total Assets27 · Mar 2022 to Mar 2026
- Depreciation, Segment Information22 · Mar 2022 to Mar 2026
- Average number of temporary employees17 · Mar 2022 to Mar 2026
- Goodwill4 · Mar 2025 to Mar 2026
- Impairment losses3 · Mar 2025
- Impairment losses - EL3 · Mar 2022
- Amortization of goodwill-SGA2 · Mar 2026
Segments
403 factsFigures broken down by business line, region, product or another axis the company reports on.
Operating segments7 members · 403 facts
- OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember83 · Jun 2021 to Sep 2026
- TotalOfReportableSegmentsAndOthersMember83 · Jun 2021 to Sep 2026
- PharmaceuticalBusinessReportableSegmentsMember73 · Jun 2021 to Sep 2026
- AnimalHealthBusinessReportableSegmentsMember69 · Jun 2021 to Sep 2026
- ReconcilingItemsMember61 · Jun 2021 to Sep 2026
- OverseaBusinessReportableSegmentsMember19 · Mar 2025 to Sep 2026
- CorporateSharedMember15 · Mar 2022 to Mar 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Ask about this company in your AI model
Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.
Use FactIQ to get the revenue, net income and operating income of ASKA Pharmaceutical Holdings CO., Ltd. (4886.T) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 19, 2026) and refreshed every few hours.